AU2022291691A1

AU2022291691A1 - Synthetic cellular membrane chemical ionophore delivery system comprising hexa-aqua ligand compositions

Synthetic cellular membrane chemical ionophore delivery system comprising hexa-aqua ligand compositions Download PDF

Info

Publication number: AU2022291691A1
Authority: AU; Australia
Prior art keywords: composition; metal; aqua; equal; group
Prior art date: 2021-06-16
Legal status : Pending

Application number

AU2022291691A

Other languages

English (en)

Inventor

Michael Kenneth KRYSIAK

Jasen Eric PETERSEN

Kevin Walton RUDE

Current Assignee

Ionic Alliance Holdings LLC

Original Assignee

Ionic Alliance Holdings LLC

Priority date

2021-06-16

Filing date

2022-05-23

Publication date

2024-02-01

2021-07-30 Priority claimed from US17/390,743 external-priority patent/US20220226371A1/en

2022-05-23 Application filed by Ionic Alliance Holdings LLC filed Critical Ionic Alliance Holdings LLC

2024-02-01 Publication of AU2022291691A1 publication Critical patent/AU2022291691A1/en

Status Pending legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 213
239000003446 ligand Substances 0.000 title claims description 83
230000001413 cellular effect Effects 0.000 title claims description 29
230000000236 ionophoric effect Effects 0.000 title abstract description 33
239000002555 ionophore Substances 0.000 title abstract description 32
239000012528 membrane Substances 0.000 title abstract description 25
238000012384 transportation and delivery Methods 0.000 title description 29
239000000126 substance Substances 0.000 title description 18
150000002500 ions Chemical class 0.000 claims abstract description 48
229910052751 metal Inorganic materials 0.000 claims description 91
239000002184 metal Substances 0.000 claims description 88
238000000034 method Methods 0.000 claims description 68
150000001875 compounds Chemical class 0.000 claims description 61
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 46
239000000243 solution Substances 0.000 claims description 42
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
238000009472 formulation Methods 0.000 claims description 38
238000011282 treatment Methods 0.000 claims description 38
201000010099 disease Diseases 0.000 claims description 33
229910052725 zinc Inorganic materials 0.000 claims description 32
229910052749 magnesium Inorganic materials 0.000 claims description 25
150000003839 salts Chemical class 0.000 claims description 22
-1 superoxide ion Chemical class 0.000 claims description 19
150000001768 cations Chemical class 0.000 claims description 18
235000016709 nutrition Nutrition 0.000 claims description 18
229910052802 copper Inorganic materials 0.000 claims description 16
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 13
239000007864 aqueous solution Substances 0.000 claims description 13
150000004677 hydrates Chemical class 0.000 claims description 13
JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 12
229910052739 hydrogen Inorganic materials 0.000 claims description 11
239000012453 solvate Substances 0.000 claims description 11
229910052757 nitrogen Inorganic materials 0.000 claims description 10
229910052700 potassium Inorganic materials 0.000 claims description 9
229910052717 sulfur Inorganic materials 0.000 claims description 9
150000001450 anions Chemical class 0.000 claims description 8
229910052500 inorganic mineral Inorganic materials 0.000 claims description 8
239000011707 mineral Substances 0.000 claims description 8
230000000699 topical effect Effects 0.000 claims description 8
229910052748 manganese Inorganic materials 0.000 claims description 7
238000012261 overproduction Methods 0.000 claims description 7
229910052708 sodium Inorganic materials 0.000 claims description 7
229910052791 calcium Inorganic materials 0.000 claims description 6
IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 claims description 5
229910052709 silver Inorganic materials 0.000 claims description 5
230000009469 supplementation Effects 0.000 claims description 5
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
239000002537 cosmetic Substances 0.000 claims description 4
229910052737 gold Inorganic materials 0.000 claims description 4
229910052742 iron Inorganic materials 0.000 claims description 4
VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 3
229910052794 bromium Inorganic materials 0.000 claims description 3
229910052801 chlorine Inorganic materials 0.000 claims description 3
238000003745 diagnosis Methods 0.000 claims description 3
239000007972 injectable composition Substances 0.000 claims description 3
238000010253 intravenous injection Methods 0.000 claims description 3
229910052740 iodine Inorganic materials 0.000 claims description 3
230000033116 oxidation-reduction process Effects 0.000 claims description 3
238000001514 detection method Methods 0.000 claims description 2
238000002663 nebulization Methods 0.000 claims description 2
230000005855 radiation Effects 0.000 claims description 2
238000010254 subcutaneous injection Methods 0.000 claims description 2
239000007929 subcutaneous injection Substances 0.000 claims description 2
239000012049 topical pharmaceutical composition Substances 0.000 claims description 2
238000002604 ultrasonography Methods 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 1
235000011007 phosphoric acid Nutrition 0.000 claims 1
210000004027 cell Anatomy 0.000 description 68
206010028980 Neoplasm Diseases 0.000 description 61
229910001868 water Inorganic materials 0.000 description 54
108010012715 Superoxide dismutase Proteins 0.000 description 52
102000019197 Superoxide Dismutase Human genes 0.000 description 51
201000011510 cancer Diseases 0.000 description 37
239000011777 magnesium Substances 0.000 description 36
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
239000011701 zinc Substances 0.000 description 36
229910021645 metal ion Inorganic materials 0.000 description 28
239000003642 reactive oxygen metabolite Substances 0.000 description 27
230000036542 oxidative stress Effects 0.000 description 26
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 25
239000003814 drug Substances 0.000 description 25
210000004379 membrane Anatomy 0.000 description 24
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 23
230000000694 effects Effects 0.000 description 23
238000004519 manufacturing process Methods 0.000 description 23
239000003963 antioxidant agent Substances 0.000 description 22
239000010949 copper Substances 0.000 description 22
229910052760 oxygen Inorganic materials 0.000 description 22
230000008569 process Effects 0.000 description 22
235000006708 antioxidants Nutrition 0.000 description 21
239000001301 oxygen Substances 0.000 description 21
230000009471 action Effects 0.000 description 20
238000006243 chemical reaction Methods 0.000 description 20
150000003254 radicals Chemical class 0.000 description 19
241000894007 species Species 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
230000003078 antioxidant effect Effects 0.000 description 18
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 18
230000009467 reduction Effects 0.000 description 18
239000007845 reactive nitrogen species Substances 0.000 description 16
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 15
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 15
230000006870 function Effects 0.000 description 15
239000007843 reactive sulfur species Substances 0.000 description 15
229940079593 drug Drugs 0.000 description 14
150000002739 metals Chemical class 0.000 description 14
150000001412 amines Chemical class 0.000 description 13
230000006907 apoptotic process Effects 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
230000007246 mechanism Effects 0.000 description 13
230000002503 metabolic effect Effects 0.000 description 13
235000015097 nutrients Nutrition 0.000 description 13
230000032258 transport Effects 0.000 description 13
230000004102 tricarboxylic acid cycle Effects 0.000 description 13
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
208000023275 Autoimmune disease Diseases 0.000 description 12
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
239000002253 acid Substances 0.000 description 12
230000007812 deficiency Effects 0.000 description 12
230000037361 pathway Effects 0.000 description 12
210000003491 skin Anatomy 0.000 description 12
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 11
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 11
229910021529 ammonia Inorganic materials 0.000 description 11
230000001093 anti-cancer Effects 0.000 description 11
230000000845 anti-microbial effect Effects 0.000 description 11
210000000170 cell membrane Anatomy 0.000 description 11
230000013632 homeostatic process Effects 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
208000015181 infectious disease Diseases 0.000 description 11
229910001425 magnesium ion Inorganic materials 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
239000007858 starting material Substances 0.000 description 11
102000004190 Enzymes Human genes 0.000 description 10
108090000790 Enzymes Proteins 0.000 description 10
230000004060 metabolic process Effects 0.000 description 10
210000003470 mitochondria Anatomy 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
239000001257 hydrogen Substances 0.000 description 9
239000011572 manganese Substances 0.000 description 9
PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 9
244000052769 pathogen Species 0.000 description 9
239000000047 product Substances 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
125000002091 cationic group Chemical group 0.000 description 8
210000001035 gastrointestinal tract Anatomy 0.000 description 8
230000034659 glycolysis Effects 0.000 description 8
231100000252 nontoxic Toxicity 0.000 description 8
230000003000 nontoxic effect Effects 0.000 description 8
230000001717 pathogenic effect Effects 0.000 description 8
230000002265 prevention Effects 0.000 description 8
238000001228 spectrum Methods 0.000 description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 7
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
230000009056 active transport Effects 0.000 description 7
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 7
229910052921 ammonium sulfate Inorganic materials 0.000 description 7
235000011130 ammonium sulphate Nutrition 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
230000008859 change Effects 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000027721 electron transport chain Effects 0.000 description 7
235000010755 mineral Nutrition 0.000 description 7
229910000069 nitrogen hydride Inorganic materials 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical class [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 7
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
239000011591 potassium Substances 0.000 description 7
238000011160 research Methods 0.000 description 7
239000011734 sodium Substances 0.000 description 7
239000011593 sulfur Substances 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
108090000862 Ion Channels Proteins 0.000 description 6
102000004310 Ion Channels Human genes 0.000 description 6
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
238000013459 approach Methods 0.000 description 6
230000009286 beneficial effect Effects 0.000 description 6
230000031018 biological processes and functions Effects 0.000 description 6
239000011575 calcium Substances 0.000 description 6
230000030833 cell death Effects 0.000 description 6
230000002255 enzymatic effect Effects 0.000 description 6
230000036541 health Effects 0.000 description 6
230000003993 interaction Effects 0.000 description 6
201000001441 melanoma Diseases 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
201000011519 neuroendocrine tumor Diseases 0.000 description 6
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 6
230000001590 oxidative effect Effects 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000011669 selenium Substances 0.000 description 6
MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
230000001988 toxicity Effects 0.000 description 6
231100000419 toxicity Toxicity 0.000 description 6
229910052723 transition metal Inorganic materials 0.000 description 6
150000003624 transition metals Chemical class 0.000 description 6
241000894006 Bacteria Species 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
206010027476 Metastases Diseases 0.000 description 5
239000008186 active pharmaceutical agent Substances 0.000 description 5
125000004429 atom Chemical group 0.000 description 5
230000001363 autoimmune Effects 0.000 description 5
230000008901 benefit Effects 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
230000005754 cellular signaling Effects 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
239000011521 glass Substances 0.000 description 5
239000010931 gold Substances 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
229910000000 metal hydroxide Inorganic materials 0.000 description 5
150000004692 metal hydroxides Chemical class 0.000 description 5
230000009401 metastasis Effects 0.000 description 5
239000011785 micronutrient Substances 0.000 description 5
235000013369 micronutrients Nutrition 0.000 description 5
238000002156 mixing Methods 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
238000007254 oxidation reaction Methods 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
230000035479 physiological effects, processes and functions Effects 0.000 description 5
230000003244 pro-oxidative effect Effects 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
230000027756 respiratory electron transport chain Effects 0.000 description 5
238000003756 stirring Methods 0.000 description 5
238000012546 transfer Methods 0.000 description 5
WWILHZQYNPQALT-UHFFFAOYSA-N 2-methyl-2-morpholin-4-ylpropanal Chemical compound O=CC(C)(C)N1CCOCC1 WWILHZQYNPQALT-UHFFFAOYSA-N 0.000 description 4
208000024827 Alzheimer disease Diseases 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
241000233866 Fungi Species 0.000 description 4
208000007465 Giant cell arteritis Diseases 0.000 description 4
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
241000700605 Viruses Species 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
235000011114 ammonium hydroxide Nutrition 0.000 description 4
230000003042 antagnostic effect Effects 0.000 description 4
230000008827 biological function Effects 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000004098 cellular respiration Effects 0.000 description 4
239000011651 chromium Substances 0.000 description 4
230000007123 defense Effects 0.000 description 4
230000006806 disease prevention Effects 0.000 description 4
210000003722 extracellular fluid Anatomy 0.000 description 4
210000004536 heart mitochondria Anatomy 0.000 description 4
DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
210000002311 liver mitochondria Anatomy 0.000 description 4
230000037353 metabolic pathway Effects 0.000 description 4
230000002438 mitochondrial effect Effects 0.000 description 4
230000004898 mitochondrial function Effects 0.000 description 4
230000035772 mutation Effects 0.000 description 4
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
230000035515 penetration Effects 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
230000010282 redox signaling Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
229910052711 selenium Inorganic materials 0.000 description 4
JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
206010043207 temporal arteritis Diseases 0.000 description 4
229940100611 topical cream Drugs 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 3
208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
208000017667 Chronic Disease Diseases 0.000 description 3
208000011038 Cold agglutinin disease Diseases 0.000 description 3
201000004624 Dermatitis Diseases 0.000 description 3
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 3
206010019939 Herpes gestationis Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
239000000232 Lipid Bilayer Substances 0.000 description 3
206010028851 Necrosis Diseases 0.000 description 3
208000008589 Obesity Diseases 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
208000008223 Pemphigoid Gestationis Diseases 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
206010038389 Renal cancer Diseases 0.000 description 3
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
208000000453 Skin Neoplasms Diseases 0.000 description 3
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
102000008221 Superoxide Dismutase-1 Human genes 0.000 description 3
108010021188 Superoxide Dismutase-1 Proteins 0.000 description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
125000000129 anionic group Chemical group 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
230000001640 apoptogenic effect Effects 0.000 description 3
208000011775 arteriosclerosis disease Diseases 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
239000002585 base Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
229910052804 chromium Inorganic materials 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
201000001981 dermatomyositis Diseases 0.000 description 3
229910052805 deuterium Inorganic materials 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
229940000406 drug candidate Drugs 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
230000002124 endocrine Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000003777 experimental drug Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
201000007162 hidradenitis suppurativa Diseases 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
206010025135 lupus erythematosus Diseases 0.000 description 3
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 3
238000002705 metabolomic analysis Methods 0.000 description 3
230000001431 metabolomic effect Effects 0.000 description 3
229960003085 meticillin Drugs 0.000 description 3
230000003278 mimic effect Effects 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
206010065579 multifocal motor neuropathy Diseases 0.000 description 3
230000017074 necrotic cell death Effects 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
208000008795 neuromyelitis optica Diseases 0.000 description 3
229910052759 nickel Inorganic materials 0.000 description 3
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
230000035764 nutrition Effects 0.000 description 3
208000019180 nutritional disease Diseases 0.000 description 3
235000020824 obesity Nutrition 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
230000009057 passive transport Effects 0.000 description 3
230000007170 pathology Effects 0.000 description 3
230000035699 permeability Effects 0.000 description 3
229910052697 platinum Inorganic materials 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
201000000849 skin cancer Diseases 0.000 description 3
229910001415 sodium ion Inorganic materials 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
230000035882 stress Effects 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000008685 targeting Effects 0.000 description 3
239000010936 titanium Substances 0.000 description 3
235000013343 vitamin Nutrition 0.000 description 3
239000011782 vitamin Substances 0.000 description 3
229930003231 vitamin Natural products 0.000 description 3
229940088594 vitamin Drugs 0.000 description 3
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
230000002407 ATP formation Effects 0.000 description 2
208000008190 Agammaglobulinemia Diseases 0.000 description 2
208000032671 Allergic granulomatous angiitis Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
KSSJBGNOJJETTC-UHFFFAOYSA-N COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC Chemical compound COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC KSSJBGNOJJETTC-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
208000005024 Castleman disease Diseases 0.000 description 2
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 2
208000006344 Churg-Strauss Syndrome Diseases 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
208000028399 Critical Illness Diseases 0.000 description 2
208000021866 Dressler syndrome Diseases 0.000 description 2
206010064212 Eosinophilic oesophagitis Diseases 0.000 description 2
241000192125 Firmicutes Species 0.000 description 2
201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000003084 Graves Ophthalmopathy Diseases 0.000 description 2
201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 2
206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
208000031814 IgA Vasculitis Diseases 0.000 description 2
208000028622 Immune thrombocytopenia Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
208000005615 Interstitial Cystitis Diseases 0.000 description 2
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
UJVHVMNGOZXSOZ-VKHMYHEASA-N L-BMAA Chemical compound CNC[C@H](N)C(O)=O UJVHVMNGOZXSOZ-VKHMYHEASA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000012309 Linear IgA disease Diseases 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
208000016604 Lyme disease Diseases 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
108090000301 Membrane transport proteins Proteins 0.000 description 2
102000003939 Membrane transport proteins Human genes 0.000 description 2
108090000157 Metallothionein Proteins 0.000 description 2
102000003792 Metallothionein Human genes 0.000 description 2
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
208000003250 Mixed connective tissue disease Diseases 0.000 description 2
ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
229910003202 NH4 Inorganic materials 0.000 description 2
229910002651 NO3 Inorganic materials 0.000 description 2
206010028767 Nasal sinus cancer Diseases 0.000 description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 2
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
206010034277 Pemphigoid Diseases 0.000 description 2
208000031845 Pernicious anaemia Diseases 0.000 description 2
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 2
208000006265 Renal cell carcinoma Diseases 0.000 description 2
208000005793 Restless legs syndrome Diseases 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
206010072148 Stiff-Person syndrome Diseases 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
206010042276 Subacute endocarditis Diseases 0.000 description 2
206010042742 Sympathetic ophthalmia Diseases 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 2
208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
108010059993 Vancomycin Proteins 0.000 description 2
230000006682 Warburg effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
208000027137 acute motor axonal neuropathy Diseases 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000001775 anti-pathogenic effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
238000011319 anticancer therapy Methods 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
229910052787 antimony Inorganic materials 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
229910052785 arsenic Inorganic materials 0.000 description 2
238000003556 assay Methods 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
208000027625 autoimmune inner ear disease Diseases 0.000 description 2
230000006399 behavior Effects 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000007321 biological mechanism Effects 0.000 description 2
229910052797 bismuth Inorganic materials 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
229910052793 cadmium Inorganic materials 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
230000003915 cell function Effects 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
239000013626 chemical specie Substances 0.000 description 2
230000003034 chemosensitisation Effects 0.000 description 2
239000006114 chemosensitizer Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
229910017052 cobalt Inorganic materials 0.000 description 2
239000010941 cobalt Substances 0.000 description 2
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
229940000425 combination drug Drugs 0.000 description 2
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
238000002716 delivery method Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
238000001784 detoxification Methods 0.000 description 2
230000001627 detrimental effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
230000001804 emulsifying effect Effects 0.000 description 2
230000006353 environmental stress Effects 0.000 description 2
201000000708 eosinophilic esophagitis Diseases 0.000 description 2
235000021321 essential mineral Nutrition 0.000 description 2
229910001851 flerovium Inorganic materials 0.000 description 2
235000012041 food component Nutrition 0.000 description 2
239000000446 fuel Substances 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
229910052732 germanium Inorganic materials 0.000 description 2
208000003884 gestational trophoblastic disease Diseases 0.000 description 2
208000002557 hidradenitis Diseases 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
230000001146 hypoxic effect Effects 0.000 description 2
DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
230000028993 immune response Effects 0.000 description 2
208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
201000008319 inclusion body myositis Diseases 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
201000002313 intestinal cancer Diseases 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
230000019948 ion homeostasis Effects 0.000 description 2
230000037427 ion transport Effects 0.000 description 2
150000008040 ionic compounds Chemical class 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
230000007774 longterm Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 2
239000000463 material Substances 0.000 description 2
230000009061 membrane transport Effects 0.000 description 2
229910052753 mercury Inorganic materials 0.000 description 2
229910001509 metal bromide Inorganic materials 0.000 description 2
229910001510 metal chloride Inorganic materials 0.000 description 2
229910001511 metal iodide Inorganic materials 0.000 description 2
229910001960 metal nitrate Inorganic materials 0.000 description 2
244000005700 microbiome Species 0.000 description 2
206010063344 microscopic polyangiitis Diseases 0.000 description 2
229910052750 molybdenum Inorganic materials 0.000 description 2
239000011733 molybdenum Substances 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
239000010955 niobium Substances 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000004792 oxidative damage Effects 0.000 description 2
230000010627 oxidative phosphorylation Effects 0.000 description 2
201000005580 palindromic rheumatism Diseases 0.000 description 2
244000045947 parasite Species 0.000 description 2
201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
208000028173 post-traumatic stress disease Diseases 0.000 description 2
238000003918 potentiometric titration Methods 0.000 description 2
230000004224 protection Effects 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000006479 redox reaction Methods 0.000 description 2
201000010174 renal carcinoma Diseases 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000010948 rhodium Substances 0.000 description 2
239000000932 sedative agent Substances 0.000 description 2
239000004332 silver Substances 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
230000008093 supporting effect Effects 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
229910052718 tin Inorganic materials 0.000 description 2
229910052719 titanium Inorganic materials 0.000 description 2
238000000954 titration curve Methods 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
229910052721 tungsten Inorganic materials 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
229910052720 vanadium Inorganic materials 0.000 description 2
LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 2
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
229960003165 vancomycin Drugs 0.000 description 2
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
230000002792 vascular Effects 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000001363 water suppression through gradient tailored excitation Methods 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
206010001935 American trypanosomiasis Diseases 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
206010061424 Anal cancer Diseases 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
208000007860 Anus Neoplasms Diseases 0.000 description 1
102000010637 Aquaporins Human genes 0.000 description 1
108010063290 Aquaporins Proteins 0.000 description 1
206010003267 Arthritis reactive Diseases 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
206010064539 Autoimmune myocarditis Diseases 0.000 description 1
206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
206010004272 Benign hydatidiform mole Diseases 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
201000006390 Brachial Plexus Neuritis Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
239000007848 Bronsted acid Substances 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
241001678559 COVID-19 virus Species 0.000 description 1
201000002829 CREST Syndrome Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
208000024699 Chagas disease Diseases 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
208000009043 Chemical Burns Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010008609 Cholangitis sclerosing Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
208000010007 Cogan syndrome Diseases 0.000 description 1
206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
208000034657 Convalescence Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010011258 Coxsackie myocarditis Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
230000007067 DNA methylation Effects 0.000 description 1
206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
208000009129 Ear Neoplasms Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
206010015226 Erythema nodosum Diseases 0.000 description 1
206010051814 Eschar Diseases 0.000 description 1
208000000289 Esophageal Achalasia Diseases 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
208000004332 Evans syndrome Diseases 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
208000016185 Gastric linitis plastica Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019263 Heart block congenital Diseases 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
208000006937 Hydatidiform mole Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
208000010159 IgA glomerulonephritis Diseases 0.000 description 1
206010021263 IgA nephropathy Diseases 0.000 description 1
208000021330 IgG4-related disease Diseases 0.000 description 1
208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
208000031781 Immunoglobulin G4 related sclerosing disease Diseases 0.000 description 1
208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
241000712431 Influenza A virus Species 0.000 description 1
206010022557 Intermediate uveitis Diseases 0.000 description 1
108010083687 Ion Pumps Proteins 0.000 description 1
102000006391 Ion Pumps Human genes 0.000 description 1
108091006671 Ion Transporter Proteins 0.000 description 1
102000037862 Ion Transporter Human genes 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000011200 Kawasaki disease Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
206010023825 Laryngeal cancer Diseases 0.000 description 1
229910052766 Lawrencium Inorganic materials 0.000 description 1
208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
229910052765 Lutetium Inorganic materials 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
208000008167 Magnesium Deficiency Diseases 0.000 description 1
206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
208000027530 Meniere disease Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
208000024599 Mooren ulcer Diseases 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
208000029578 Muscle disease Diseases 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010029229 Neuralgic amyotrophy Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000033792 Neuroendocrine tumor of the rectum Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
206010030136 Oesophageal achalasia Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
208000003435 Optic Neuritis Diseases 0.000 description 1
206010031096 Oropharyngeal cancer Diseases 0.000 description 1
206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
208000025174 PANDAS Diseases 0.000 description 1
206010053869 POEMS syndrome Diseases 0.000 description 1
208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000004788 Pars Planitis Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
208000031732 Post-Lyme Disease Syndrome Diseases 0.000 description 1
208000004347 Postpericardiotomy Syndrome Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
208000006930 Pseudomyxoma Peritonei Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
230000010757 Reduction Activity Effects 0.000 description 1
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
206010061934 Salivary gland cancer Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
206010040742 Sinus congestion Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
229920002385 Sodium hyaluronate Polymers 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
206010041925 Staphylococcal infections Diseases 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
208000002286 Susac Syndrome Diseases 0.000 description 1
208000001106 Takayasu Arteritis Diseases 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
229910052771 Terbium Inorganic materials 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010071574 Testicular autoimmunity Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
210000004241 Th2 cell Anatomy 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
206010062129 Tongue neoplasm Diseases 0.000 description 1
206010044002 Tonsil cancer Diseases 0.000 description 1
208000006842 Tonsillar Neoplasms Diseases 0.000 description 1
208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
241000223109 Trypanosoma cruzi Species 0.000 description 1
108700036309 Type I Plasminogen Deficiency Proteins 0.000 description 1
206010064996 Ulcerative keratitis Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
206010048259 Zinc deficiency Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
201000000621 achalasia Diseases 0.000 description 1
208000009621 actinic keratosis Diseases 0.000 description 1
239000012190 activator Substances 0.000 description 1
208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
208000024447 adrenal gland neoplasm Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
229940060265 aldara Drugs 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003712 anti-aging effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
230000002223 anti-pathogen Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
238000002802 antimicrobial activity assay Methods 0.000 description 1
WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000005975 antitumor immune response Effects 0.000 description 1
201000011165 anus cancer Diseases 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
230000005775 apoptotic pathway Effects 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
239000005667 attractant Substances 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
208000006424 autoimmune oophoritis Diseases 0.000 description 1
201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
206010071578 autoimmune retinopathy Diseases 0.000 description 1
208000029407 autoimmune urticaria Diseases 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
230000004900 autophagic degradation Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
229910052790 beryllium Inorganic materials 0.000 description 1
ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
208000026900 bile duct neoplasm Diseases 0.000 description 1
239000011942 biocatalyst Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960000106 biosimilars Drugs 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000005098 blood-cerebrospinal fluid barrier Anatomy 0.000 description 1
229910021475 bohrium Inorganic materials 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
238000002815 broth microdilution Methods 0.000 description 1
150000007528 brønsted-lowry bases Chemical class 0.000 description 1
229940046011 buccal tablet Drugs 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000004611 cancer cell death Effects 0.000 description 1
239000003560 cancer drug Substances 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000032677 cell aging Effects 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
230000011748 cell maturation Effects 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
230000036978 cell physiology Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
230000010001 cellular homeostasis Effects 0.000 description 1
230000010904 cellular ion homeostasis Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000004715 cellular signal transduction Effects 0.000 description 1
230000006364 cellular survival Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000031902 chemoattractant activity Effects 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
229940068682 chewable tablet Drugs 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
208000024376 chronic urticaria Diseases 0.000 description 1
201000010002 cicatricial pemphigoid Diseases 0.000 description 1
238000004581 coalescence Methods 0.000 description 1
XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
230000037410 cognitive enhancement Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
201000004395 congenital heart block Diseases 0.000 description 1
229940039231 contrast media Drugs 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
229910001850 copernicium Inorganic materials 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229910001431 copper ion Inorganic materials 0.000 description 1
108010066540 copper thionein Proteins 0.000 description 1
201000003278 cryoglobulinemia Diseases 0.000 description 1
208000030381 cutaneous melanoma Diseases 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
201000002293 dendritic cell sarcoma Diseases 0.000 description 1
208000002925 dental caries Diseases 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
230000016994 digestive system process Effects 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000007323 disproportionation reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
229910021479 dubnium Inorganic materials 0.000 description 1
208000019479 dysautonomia Diseases 0.000 description 1
208000031083 ear cancer Diseases 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000005684 electric field Effects 0.000 description 1
238000005370 electroosmosis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
231100000333 eschar Toxicity 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
210000003236 esophagogastric junction Anatomy 0.000 description 1
235000020774 essential nutrients Nutrition 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003090 exacerbative effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000007185 extracellular pathway Effects 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
208000024519 eye neoplasm Diseases 0.000 description 1
239000004744 fabric Substances 0.000 description 1
208000002980 facial hemiatrophy Diseases 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229910052730 francium Inorganic materials 0.000 description 1
KLMCZVJOEAUDNE-UHFFFAOYSA-N francium atom Chemical compound [Fr] KLMCZVJOEAUDNE-UHFFFAOYSA-N 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
201000010175 gallbladder cancer Diseases 0.000 description 1
229910052733 gallium Inorganic materials 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000007792 gaseous phase Substances 0.000 description 1
201000009129 gastric neuroendocrine neoplasm Diseases 0.000 description 1
GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
208000018090 giant cell myocarditis Diseases 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
208000027096 gram-negative bacterial infections Diseases 0.000 description 1
208000027136 gram-positive bacterial infections Diseases 0.000 description 1
229910052735 hafnium Inorganic materials 0.000 description 1
VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
229910021473 hassium Inorganic materials 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000005802 health problem Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
230000001632 homeopathic effect Effects 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
230000002706 hydrostatic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
229960002751 imiquimod Drugs 0.000 description 1
229940003788 imiquimod topical cream Drugs 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000008676 import Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
210000004020 intracellular membrane Anatomy 0.000 description 1
238000002642 intravenous therapy Methods 0.000 description 1
238000009114 investigational therapy Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000002154 ionophoretic effect Effects 0.000 description 1
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
230000002361 ketogenic effect Effects 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
229910052743 krypton Inorganic materials 0.000 description 1
DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
206010023841 laryngeal neoplasm Diseases 0.000 description 1
CNQCVBJFEGMYDW-UHFFFAOYSA-N lawrencium atom Chemical compound [Lr] CNQCVBJFEGMYDW-UHFFFAOYSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
206010071570 ligneous conjunctivitis Diseases 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
208000028830 lung neuroendocrine neoplasm Diseases 0.000 description 1
OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
210000004880 lymph fluid Anatomy 0.000 description 1
235000004764 magnesium deficiency Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
208000022924 malignant ear neoplasm Diseases 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000007726 management method Methods 0.000 description 1
229940099596 manganese sulfate Drugs 0.000 description 1
239000011702 manganese sulphate Substances 0.000 description 1
235000007079 manganese sulphate Nutrition 0.000 description 1
SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
208000029586 mediastinal germ cell tumor Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000008384 membrane barrier Effects 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
210000000716 merkel cell Anatomy 0.000 description 1
238000010197 meta-analysis Methods 0.000 description 1
231100000783 metal toxicity Toxicity 0.000 description 1
150000001455 metallic ions Chemical class 0.000 description 1
229910052752 metalloid Inorganic materials 0.000 description 1
150000002738 metalloids Chemical class 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000003595 mist Substances 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
230000004065 mitochondrial dysfunction Effects 0.000 description 1
230000006677 mitochondrial metabolism Effects 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
230000036640 muscle relaxation Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229950006238 nadide Drugs 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
229910052754 neon Inorganic materials 0.000 description 1
GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000000441 neoplastic stem cell Anatomy 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
208000029974 neurofibrosarcoma Diseases 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000004112 neuroprotection Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
229910052758 niobium Inorganic materials 0.000 description 1
GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
230000008599 nitrosative stress Effects 0.000 description 1
238000012148 non-surgical treatment Methods 0.000 description 1
229910052755 nonmetal Inorganic materials 0.000 description 1
231100001200 nonototoxic Toxicity 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
235000018343 nutrient deficiency Nutrition 0.000 description 1
235000021231 nutrient uptake Nutrition 0.000 description 1
201000008106 ocular cancer Diseases 0.000 description 1
208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
201000005737 orchitis Diseases 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
201000006958 oropharynx cancer Diseases 0.000 description 1
229910052762 osmium Inorganic materials 0.000 description 1
SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
RECVMTHOQWMYFX-UHFFFAOYSA-N oxygen(1+) dihydride Chemical compound [OH2+] RECVMTHOQWMYFX-UHFFFAOYSA-N 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
201000007052 paranasal sinus cancer Diseases 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000037050 permeability transition Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
230000029553 photosynthesis Effects 0.000 description 1
238000010672 photosynthesis Methods 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229910052699 polonium Inorganic materials 0.000 description 1
HZEBHPIOVYHPMT-UHFFFAOYSA-N polonium atom Chemical compound [Po] HZEBHPIOVYHPMT-UHFFFAOYSA-N 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
238000004313 potentiometry Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
208000018290 primary dysautonomia Diseases 0.000 description 1
201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
230000009046 primary transport Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
208000009954 pyoderma gangrenosum Diseases 0.000 description 1
238000004451 qualitative analysis Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
229910052705 radium Inorganic materials 0.000 description 1
HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
229910052704 radon Inorganic materials 0.000 description 1
SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
238000011084 recovery Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000007363 regulatory process Effects 0.000 description 1
208000009169 relapsing polychondritis Diseases 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000003938 response to stress Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
229910052701 rubidium Inorganic materials 0.000 description 1
IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
229910021481 rutherfordium Inorganic materials 0.000 description 1
YGPLJIIQQIDVFJ-UHFFFAOYSA-N rutherfordium atom Chemical compound [Rf] YGPLJIIQQIDVFJ-UHFFFAOYSA-N 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
229910052706 scandium Inorganic materials 0.000 description 1
SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
208000010157 sclerosing cholangitis Diseases 0.000 description 1
229910021477 seaborgium Inorganic materials 0.000 description 1
208000011571 secondary malignant neoplasm Diseases 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
VSZWPYCFIRKVQL-UHFFFAOYSA-N selanylidenegallium;selenium Chemical compound [Se].[Se]=[Ga].[Se]=[Ga] VSZWPYCFIRKVQL-UHFFFAOYSA-N 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
230000009131 signaling function Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000010944 silver (metal) Substances 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
229940126586 small molecule drug Drugs 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000000050 smooth muscle relaxant Substances 0.000 description 1
229940010747 sodium hyaluronate Drugs 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
235000014347 soups Nutrition 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000000434 stratum corneum Anatomy 0.000 description 1
210000003699 striated muscle Anatomy 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000000475 sunscreen effect Effects 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229910052715 tantalum Inorganic materials 0.000 description 1
GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
229910052713 technetium Inorganic materials 0.000 description 1
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
229910052714 tellurium Inorganic materials 0.000 description 1
PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
210000003411 telomere Anatomy 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
210000001578 tight junction Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000009092 tissue dysfunction Effects 0.000 description 1
201000006134 tongue cancer Diseases 0.000 description 1
239000008009 topical excipient Substances 0.000 description 1
229940042129 topical gel Drugs 0.000 description 1
229940126702 topical medication Drugs 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000013271 transdermal drug delivery Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
229910001428 transition metal ion Inorganic materials 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000007723 transport mechanism Effects 0.000 description 1
208000009174 transverse myelitis Diseases 0.000 description 1
230000008733 trauma Effects 0.000 description 1
208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
230000001573 trophoblastic effect Effects 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
239000010937 tungsten Substances 0.000 description 1
230000004143 urea cycle Effects 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
206010046885 vaginal cancer Diseases 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
208000036440 well differentiated low or intermediate grade neuroendocrine tumor of rectum Diseases 0.000 description 1
229910052724 xenon Inorganic materials 0.000 description 1
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
229940006486 zinc cation Drugs 0.000 description 1